biologic

Simponi Aria

golimumab

Loss of exclusivity—loss of exclusivity
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameSimponi Aria
Active ingredientgolimumab
Strength50MG/4ML (12.5MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.